Haleon H1 2026: Organic Revenue +2.6%, Adjusted EPS +12%, Buyback Nearly Complete
HLN sits 16% above its 52-week low of $8.65.
Summary
Haleon reported H1 2026 organic revenue growth of 2.6% and adjusted diluted EPS of 10.3p, up 12%. The company reaffirmed its full-year guidance, declared a 9% higher interim dividend, and has nearly completed its £500 million share buyback.
Key Events · Earnings and Guidance · HLN
-
H1 Organic Revenue +2.6%
Group organic revenue grew 2.6%, with Oral Health up 7.3% and Pain Relief up 2.1%, offsetting a 4.7% decline in Respiratory Health due to a weak cold and flu season.
-
Adjusted EPS +12% to 10.3p
Adjusted diluted earnings per share rose 12% to 10.3p, supported by 8.2% constant currency adjusted operating profit growth and a lower share count from buybacks.
-
Interim Dividend +9% to 2.4p
The Board declared an interim dividend of 2.4 pence per share, up 9% year-on-year, consistent with the policy of paying one-third of the prior year's full-year dividend.
-
£500M Buyback 91% Complete
Haleon completed £457 million of its £500 million share buyback program for 2026, reducing the diluted share count by 1.6%.
Analysis · HLN · Industrial Applications And Services
A solid first half saw organic revenue climb 2.6% and adjusted diluted EPS reach 10.3p, a 12% increase, fueled by robust Oral Health results and productivity gains. The full-year outlook remains intact, and the interim dividend was raised 9%. With the £500 million share buyback 91% finished, a £168 million restructuring charge tied to the new operating model is expected to unlock annualized savings of £175-200 million.
At the time of this filing, HLN was trading at $10.03 on NYSE in the Industrial Applications And Services sector, with a market capitalization of approximately $44.7B. The 52-week trading range was $8.65 to $11.28. This filing was assessed with positive market sentiment and an importance score of 7 out of 10.